NCT00604721 - Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver Cancer

Interventions

DRUG

selumetinib

Given orally

OTHER

pharmacological study

Trial Locations (6)

23298

Virginia Commonwealth University, Richmond

27599

University of North Carolina, Chapel Hill

30322

Emory University, Atlanta

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

37232

Vanderbilt University, Nashville

43210

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH